MergerJul 15, 2026, 05:22 PM
Glucotrack Completes Strategic Merger with Lokahi Therapeutics
AI Summary
Glucotrack, Inc. and Lokahi Therapeutics, Inc. have completed their strategic business combination, with Lokahi Therapeutics becoming the operating and controlling business of the combined public company. Lokahi securityholders will hold approximately 90% of the combined entity on a fully diluted basis, leveraging Glucotrack's public market platform for growth and capital access. The transaction includes a planned private placement financing and establishes Glucotrack's continuous blood glucose monitoring business as a dedicated, wholly owned subsidiary. Erik Emerson has been appointed CEO of the combined company, and Paul Goode will serve as CTO and CEO of the CBGM subsidiary.
Key Highlights
- Merger between Glucotrack, Inc. and Lokahi Therapeutics, Inc. completed on July 14, 2026.
- Lokahi Therapeutics securityholders to hold approximately 90% of the combined company on a fully diluted basis.
- Glucotrack's existing stockholders will hold no less than 10.0% of the combined company.
- Transaction supported by a planned private placement financing to strengthen capital position.
- Glucotrack's continuous blood glucose monitoring (CBGM) business will operate as a wholly owned subsidiary.
- Erik Emerson appointed CEO of the combined company; Paul Goode appointed CTO and CEO of CBGM subsidiary.
- Secured convertible promissory notes issued for an aggregate principal amount of up to $5,705,128.10.
Price Impact
More from GCTK